An open label study to assess the effect of intravenous loading doses of Bondronat on bone pain in patients with breast cancer and skeletal metastases.

Trial Profile

An open label study to assess the effect of intravenous loading doses of Bondronat on bone pain in patients with breast cancer and skeletal metastases.

Completed
Phase of Trial: Phase II

Latest Information Update: 04 Sep 2013

At a glance

  • Drugs Ibandronic acid (Primary)
  • Indications Breast cancer; Cancer metastases
  • Focus Therapeutic Use
  • Sponsors Roche
  • Most Recent Events

    • 17 Jul 2009 Actual end date (Mar 2009) added as reported by ClinicalTrials.gov.
    • 17 Jul 2009 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
    • 18 Aug 2008 Planned end date changed from 1 Apr 2008 to 1 Jan 2009, according to Clinicaltrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top